Get the Stockscreener App
568.53
1.98%
10.90
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $568.53, with a volume of 493.68K.
It is up +1.98% in the last 24 hours and up +23.07% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$557.63
Open:
$558.31
24h Volume:
493.68K
Relative Volume:
0.23
Market Cap:
$214.56B
Revenue:
$43.74B
Net Income/Loss:
$6.59B
P/E Ratio:
32.86
EPS:
17.3021
Net Cash Flow:
$6.11B
1W Performance:
+0.26%
1M Performance:
+23.07%
6M Performance:
+33.01%
1Y Performance:
+3.81%
1-Day Range:
$555.06
$568.66
1-Week Range:
$555.06
$578.24
52-Week Range:
$385.46
$610.97
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
568.20 | 210.57B | 43.74B | 6.59B | 6.11B | 17.30 |
|
DHR
Danaher Corp
|
217.81 | 153.21B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
630.39 | 50.75B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
145.27 | 41.35B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
221.10 | 37.15B | 15.70B | 1.24B | 2.01B | 6.9036 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-19-25 | Initiated | William Blair | Outperform |
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Thermo Fisher to acquire clinical trial data firm Clario for $8.9B - MedTech Dive
Thermo Fisher Scientific to Acquire Clario Holdings For $8.875 Billion - citybiz
Thermo Fisher to buy Clario for $8.8bn - Yahoo Finance
Thermo Fisher Scientific to acquire Clario in $8.9B cash deal - Proactive financial news
Argus Research Adjusts Thermo Fisher Scientific Price Target to $610 From $580 - MarketScreener
Thermo Fisher to Acquire Clario for $8.875 Billion - Contract Pharma
Thermo Fisher Scientific, U.S clinical research major, invests ₹160 cr in Bengaluru for antibody research - The Hindu
Cell & Gene Therapy Quality Control Market Poised USD 22.81 Billion at 25.74% CAGR by 2034 - GlobeNewswire Inc.
Thermo Fisher to buy Clario Holdings for $8.88B - Axios
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now - Nasdaq
Thermo Fisher strikes $9.4bn acquisition of Nordic Capital and Astorg-backed Clario - Private Equity Insights
Does Thermo Fisher's 20% Rally Signal More Upside After New Pharma Partnerships? - Yahoo Finance
Thermo Fisher to buy clinical services provider Clario for up to $9.4 billion - Reuters
Thermo Fisher To Acquire Clario Holdings In A $9.4B Deal - Asianet Newsable
Thermo Fisher Scientific Inc. agreed to acquire Clario Holdings, Inc. for $9.4 bilion. - MarketScreener
Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights - BioSpace
Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 Billion - The Wall Street Journal
WilmerHale Advises Thermo Fisher Scientific on $9 Billion Acquisition of Clario - WilmerHale
Thermo Fisher Announces Acquisition of Clario Holdings - TipRanks
Media: Thermo Fisher close to USD 10bn acquisition - medwatch.com
Thermo Fisher to Buy Clinical Services Provider Clario for up to $9.4 Billion - US News Money
Thermo Fisher Scientific to acquire Clario Holdings, enabling pharma and biotech customers to accelerate innovation with deeper clinical insights - MarketScreener
PE investor group to sell clinical trial data firm Clario to Thermo Fisher Scientific for $8.9bn - pehub.com
Thermo Fisher Scientific To Acquire Clario Holdings, Enabling Pharma And Biotech Customers To Accelerate Innovation With Deeper Clinical Insights - TradingView
Thermo Fisher Scientific inaugurates expanded RnD Centre of Excellence in Bengaluru - Medical Dialogues
Research Antibodies Market to Get an Explosive Growth | Thermo - openPR.com
Thermo Fisher Scientific Expands Bengaluru R&D Center with INR 160 Cr Investment - Digital Health News
M&A News: Thermo Fisher (TMO) Nears $10B Clario Takeover to Strengthen Clinical Trial Tech - TipRanks
Thermo Fisher said to eye $10B takeover of clinical trial software firm Clario - Seeking Alpha
Thermo Fisher Scientific to accelerate life science breakthroughs with OpenAI - SelectScience
5 Revealing Analyst Questions From Thermo Fisher’s Q3 Earnings Call - Yahoo! Finance UK
Thermo Fisher Scientific inaugurates expanded R&D centre of excellence in Bengaluru - ETHRWorld.com
14-year-old Combines Origami and Physics to Engineer - GlobeNewswire
14-year-old Combines Origami and Physics to Engineer Foldable Structures for Disaster Relief Shelters; Wins $25,000 Top Award at Thermo Fisher Scientific Junior Innovators Challenge - The Manila Times
Thermo Fisher nears $10 billion takeover of Clario, FT reports - Reuters
Thermo Fisher nears $10 bln deal to acquire Clario, FT reports - Investing.com
Thermo Fisher nears $10 billion takeover of drug trial software maker Clario, FT reports - MarketScreener
Thermo Fisher nears $10 billion takeover of drug trial software maker ClarioFT - MarketScreener
Thermo Fisher strikes up to $9.4bn takeover of drug trial software maker Clario - Financial Times
Insider Sell: Gianluca Pettiti Sells Shares of Thermo Fisher Sci - GuruFocus
Can Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock hit consensus price targetsOil Prices & Daily Stock Trend Watchlist - Fundação Cultural do Pará
Thermo Fisher Scientific invests ₹160 cr to expand Bengaluru R&D centre - BusinessLine
Thermo Fisher Scientific Enables Semiconductor Manufacturers to See the Unseen with Helios MX1 PFIB-SEM - The Joplin Globe
Thermo Fisher: Measuring Clinical Supply Chain Emissions - Supply Chain Digital Magazine
Morgan Stanley Raises Price Target on Thermo Fisher Scientific to $656 From $560, Keeps Overweight Rating - MarketScreener
Thermo Fisher invests Rs 160 crore to expand Bengaluru R&D centre - Moneycontrol
Is Thermo Fisher Scientific’s Stock Rally Justified After Strategic Growth Initiatives in 2025? - simplywall.st
Thermo Fisher Enhances India's Biotechnology Landscape with R&D Expansion - Devdiscourse
Thermo Fisher invests ₹160 crore to expand Bengaluru R&D facility, to create 100 jobs - ET HealthWorld
Thermo Fisher Scientific invests Rs. 160 crore, Bengaluru R&D will create over 100 jobs - Pharmabiz.com
Thermo Fisher Scientific inaugurates expanded R&D Centre of Excellence in Bengaluru - Express Pharma
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):